Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionPinnacle Bancorp, Inc.
Latest Disclosed Ownership54 shares
Latest Disclosed Value $ 24,113
Pinnacle Bancorp, Inc. ownership in VRTX / Vertex Pharmaceuticals Incorporated

On April 22, 2026 - Pinnacle Bancorp, Inc. filed a 13F-HR form disclosing ownership of 54 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $24,113 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 22, 2026 disclosing 54 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 0.00% during the quarter. The current value of the position is $23,130 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-04-22 2026-03-31 13F Vertex Pharmctls COM 92532F100 54 0 0.00 24 0.00 0.0071
2026-01-22 2025-12-31 13F Vertex Pharmctls COM 92532F100 54 0 0.00 24 14.29 0.0072
2025-10-24 2025-09-30 13F Vertex Pharmctls COM 92532F100 54 54 21 0.0062
2023-07-13 2023-06-30 13F Vertex Pharmctls COM 92532F100 0 -31 -100.00 0 -100.00
2023-04-14 2023-03-31 13F Vertex Pharmctls COM 92532F100 31 0 0.00 10 0.0036
2023-01-24 2022-12-31 13F Vertex Pharmctls COM 92532F100 31 0 0.00 0 -100.00 0.0035
2022-10-25 2022-09-30 13F Vertex Pharmctls COM 92532F100 31 -29 -48.33 9 -47.06 0.0039
2022-07-12 2022-06-30 13F Vertex Pharmctls COM 92532F100 60 0 0.00 17 6.25 0.0070
2022-04-14 2022-03-31 13F Vertex Pharmctls COM 92532F100 60 -194 -76.38 16 -71.43 0.0056
2022-01-19 2021-12-31 13F Vertex Pharmctls COM 92532F100 254 0 0.00 56 21.74 0.0198
2021-10-12 2021-09-30 13F Vertex Pharmctls COM 92532F100 254 0 0.00 46 -9.80 0.0184
2021-07-15 2021-06-30 13F Vertex Pharmctls COM 92532F100 254 15 6.28 51 0.00 0.0233
2021-04-26 2021-03-31 13F Vertex Pharmctls COM 92532F100 239 239 51 0.0247
2019-04-05 2019-03-31 13F Vertex Pharmctls COM 92532F100 0 0 0 0.0000
2019-03-20 2018-12-31 13F Vertex Pharmctls COM 92532F100 0 -800 -100.00 0 -100.00
2017-04-17 2017-03-31 13F Vertex Pharmctls COM 92532F100 800 800 87 0.0615
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.